Comment
Author: Admin | 2025-04-28
Side effects when taking this medication. Description for MacrobidNitrofurantoin is an antibacterial agent specific for urinary tract infections. The Macrobid® brand of nitrofurantoin is a hard gelatin capsule shell containing the equivalent of 100 mg of nitrofurantoin in the form of 25 mg of nitrofurantoin macrocrystals and 75 mg of nitrofurantoin monohydrate.The chemical name of nitrofurantoin macrocrystals is 1-[[[5-nitro-2-furanyl]methylene] amino]-2,4-imidazolidinedione. The chemical structure is the following:Molecular Weight: 238.16The chemical name of nitrofurantoin monohydrate is 1-[[[5-nitro-2-furanyl]methylene] amino]-2,4-imidazolidinedione monohydrate. The chemical structure is the following:Molecular Weight: 256.17Inactive Ingredients: Each capsule contains carbomer 934P, corn starch, compressible sugar, D&C Yellow No. 10, edible gray ink, FD&C Blue No. 1, FD&C Red No. 40, gelatin, lactose, magnesium stearate, povidone, talc, and titanium dioxide. Uses for MacrobidMacrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cultureand susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence ofsuch data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, manypatients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See Clinical Studies). Urinespecimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance ofbacteriuria occurs after treatment with Macrobid, other therapeutic agents with broader tissue distribution should be selected. Inconsidering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for thedevelopment of antimicrobial resistance when agents with broader tissue distribution are utilized.Dosage for MacrobidMacrobid capsules should be taken with food.Adults And Pediatric Patients Over 12 YearsOne 100 mg capsule every 12 hours for seven days.Macrobid (Nitrofurantoin Capsules, USP) (monohydrate/macrocrystals) is available as 100 mg opaque black and yellow capsules imprinted“(band) Macrobid (band)” on one half and “52427-285” on the other.NDC: 70518-2531-00Packaging: 10 in 1 BOTTLE PLASTICStore at controlled room temperature 15°C to 30°C (59°F to 86°F).Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762. Revised: N/A Side Effects for MacrobidIn clinical trials of Macrobid, the most frequent clinical adverse events that were reported as possibly or probably drug-related were nausea(8%), headache (6%), and flatulence (1.5%). Additional clinical adverse events reported as possibly or probably drug-related occurred inless
Add Comment